MANKIND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | MANKIND | Market Cap | 92,750 Cr. | Current Price | 2,247 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 52.5 | Book Value | 376 ₹ | Dividend Yield | 0.04 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,143 ₹ | DMA 200 | 2,244 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 63.8 | MACD | 50.1 | Volume | 3,09,556 | Avg Vol 1Wk | 3,26,436 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.24 | Debt to equity | 0.47 |
| 52w Index | 41.2 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 30.1 |
📊 Mankind Pharma (MANKIND) is trading above its 50 DMA (₹2,143) and near its 200 DMA (₹2,244), showing strong short-term support with medium-term stability. RSI at 63.8 reflects bullish momentum, while MACD (50.1) confirms positive divergence. Bollinger Bands suggest price movement toward the upper band, indicating potential continuation of the uptrend. Current volume (3.09 lakh) is slightly below the 1-week average (3.26 lakh), showing steady but not aggressive participation.
💡 Optimal Entry: ₹2,220–₹2,240 (near DMA support)
🚪 Exit if Holding: Profit-taking zone around ₹2,300–₹2,350; Stop-loss below ₹2,200
📈 Trend Status: Trending upward with bullish momentum
✅ Positive
- Trading above 50 DMA and near 200 DMA support
- Strong quarterly PAT growth (₹459 Cr → ₹513 Cr)
- EPS at ₹41.3 supports earnings visibility
- DII holdings increased (+1.20%)
- ROE (13.9%) and ROCE (15.0%) show healthy efficiency
⚠️ Limitation
- High valuation (P/E 52.5 vs industry 30.1)
- FII holdings declined (-1.10%)
- PEG ratio at 6.24 indicates stretched growth-adjusted valuation
- Volume slightly below weekly average
📉 Company Negative News
- Valuation concerns due to high P/E multiples
- Reduced foreign institutional participation
📈 Company Positive News
- Strong quarterly PAT growth (+24.5%)
- DII inflows indicate domestic investor confidence
- EPS stability supports long-term earnings visibility
🏭 Industry
- Pharma sector average PE at 30.1, Mankind trades at a premium (52.5)
- Sector outlook remains strong with consistent demand visibility
🔎 Conclusion
Mankind Pharma is trending upward with bullish momentum, supported by strong fundamentals and technical positioning above key moving averages. Entry near ₹2,220–₹2,240 offers a favorable risk-reward setup, while exits around ₹2,300–₹2,350 are advisable. Despite strong earnings growth, stretched valuations and declining FII interest warrant cautious positioning for medium-term investors.